% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • burnaka Dec 25, 2011 1:48 AM Flag


    You bring up a 2007 article and entitle the post imminent buyout rumors. That is hilarious. JnJ had what about 450 million stent business and exited the bus. Abbott has better products. Bsx has recently paid 2 billion in patent infringements with more suits pending. So we have a laggard in the industry, with some nice debt and lawsuits pending and people are grasping at 2007 articles hoping to prop up the stock. The stock will bounce around some for sure, and they do have a chance to pick up some of the jnj business, jnj had 14% market share. Maybe bsx gets 100 million not enough to make a difference with 1.5 billion shares, and 4.5 billion in debt. Bsx has decent revenue, margins, but this will take time. No buyout on horizon until all the suits are done, and the debt is addressed.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The key driver going forward will be NOT paying royalties to Abbott and expansion in China and the JNJ business will be the gravy.

      We will earn 60-65 cents in 2012 and with a 15 multiple, the stock will trade at around $10.00.

      The downside is limited and the upside is about 100%.

      Finally as the market starts moving up now that the Euro debt crisis is behind us, the midcaps will start performing best and we will get additional boost from an up market.

      Buy all you can at this PPs.

23.97+0.20(+0.84%)Aug 26 4:01 PMEDT